The Journal of Practical Medicine >

2026 , Vol. 42 >Issue 2: 320 - 326

DOI: https://doi.org/10.3969/j.issn.1006-5725.2026.02.018

Treatise: Clinical Practice

Comparison of the efficacy between lauromacrogol injection combined with microwave ablation and lauromacrogol injection alone for cystic or predominantly cystic thyroid nodules

  • Yingchao CHEN ,
  • Yi CHEN ,
  • Jing CHENG ,
  • Wen ZHANG ,
  • Wenwen XIA ,
  • Huaidong SONG ,
  • Bing HAN
Expand
  • 1.Department of Endocrinology and Metabolism，Shanghai Ninth People's Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai 200011，Shanghai，China
    2. Discipline Planning Office，Shanghai Ninth People's Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai 200011，Shanghai，Chin
    3. Department of Pathology，Shanghai Ninth People's Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai 200011，Shanghai，Chin
    4. The Core Laboratory in Medical Center of Clinical Research，Shanghai Ninth People's Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai 200011，Shanghai，China

Received date: 2025-08-24

  Revised date: 2025-11-26

  Accepted date: 2025-11-28

  Online published: 2026-01-22

Fold

Abstract

Objective Comparison of the treatment efficacy between percutaneous lauromacrogol injection （PLI） combined with microwave ablation （MWA） and PLI alone for cystic or predominantly cystic thyroid nodules. Methods This study retrospectively analyzed 90 cystic or predominantly cystic thyroid nodules that were treated with either PLI or PLI+MWA at Shanghai Ninth People's Hospital from January 2021 to March 2025. All cases were confirmed to be benign through preoperative ultrasound and fine-needle aspiration. The size of the nodules was assessed by ultrasound at 1， 3， and 6 months after treatment， and the volume reduction rate （VRR） was calculated. Results A total of 81 patients （90 nodules） were incorporated into the analysis， including 20 males （24 nodules） and 61 females （66 nodules）. Among these nodules， 59 received PLI treatment， whereas 31 underwent PLI + MWA. Both PLI and PLI + MWA treatments led to a significant reduction in the volume of thyroid nodules. Although the baseline nodule volumes in the PLI + MWA group were larger than those in the PLI group ［（17.27 ± 10.49） mL vs. （12.12 ± 11.03） mL， P = 0.033］， there were no significant differences in nodule volumes between the two groups at 1， 3， and 6 months after treatment ［（4.02 ± 7.95） mL vs. （7.47 ± 6.93） mL； （2.98 ± 6.31） mL vs. （2.43 ± 2.62） mL； （3.64 ± 8.82） mL vs. （1.09 ± 2.10） mL； all P > 0.05］. Furthermore， at the 3-month ［（14.77 ± 8.48） mL vs. （8.36 ± 9.24） mL， P = 0.025］ and 6-month ［（14.53 ± 6.86） mL vs. （4.79 ± 3.99） mL， P = 0.001］ follow-ups， the PLI + MWA treatment group showed a significantly greater reduction in nodule volume from the baseline compared to the PLI-only group. One month after treatment， the VRR in the PLI group was higher than that in the PLI + MWA group ［83.44% （66.97%， 93.07%） vs. 52.53% （17.62%， 90.66%）， P = 0.011］. However， six months after the operation， the VRR in the PLI + MWA group was significantly higher than that in the PLI group ［83.44% （66.97%， 93.07%） vs. 81.68% （58.43%， 96.96%）， P = 0.019］. Moreover， six months after treatment， the cure rate （VRR > 90%） in the PLI + MWA group was significantly higher than that in the PLI group （87.5% vs. 33.3%， P = 0.024）. Conclusions Both ultrasound-guided PLI and PLI + MWA are effective therapeutic modalities for benign thyroid nodules with cystic or predominantly cystic components. Significantly， at 6 months after treatment， PLI + MWA yielded notably superior therapeutic outcomes compared to PLI monotherapy.

Key words： thyroid nodules; microwave ablation; percutaneous lauromacrogol injection; volume reduction rate

Cite this article

Yingchao CHEN , Yi CHEN , Jing CHENG , Wen ZHANG , Wenwen XIA , Huaidong SONG , Bing HAN . Comparison of the efficacy between lauromacrogol injection combined with microwave ablation and lauromacrogol injection alone for cystic or predominantly cystic thyroid nodules[J]. The Journal of Practical Medicine, 2026 , 42(2) : 320 -326 . DOI: 10.3969/j.issn.1006-5725.2026.02.018

References

[1] UPPAL N， COLLINS R， JAMES B. Thyroid nodules： Global， economic， and personal burdens［J］. Front Endocrinol （Lausanne）， 2023， 14：1113977. doi： 10.3389/fendo.2023.1113977 .
[2] KOBALY K， KIM C S， MANDEL S J. Contemporary Management of Thyroid Nodules［J］. Annu Rev Med， 2022， 73：517-528. doi： 10.1146/annurev-med-042220-015032 .
[3] YANG Z， PAN X H， HAN H T， et al. Progress in research on ablation of thyroid nodules［J］. Endokrynol Pol， 2024， 75（3）：262-266. doi： 10.5603/ep.98908 .
[4] 徐理敏，赖敏，徐栋. 甲状腺良性结节消融治疗现状与疗效影响因素的研究进展［J］. 肿瘤学杂志， 2024， 30（4）：321-327.doi： 10.11735/j.issn.1671-170X.2024.04.B009 .
[5] CLARK R D E， LUO X， ISSA P P， et al. A clinical practice review of percutaneous ethanol injection for thyroid nodules： State of the art for benign， cystic lesions［J］. Gland Surg， 2024， 13（1）：108-116. doi： 10.21037/gs-22-568 .
[6] YANG C C， HSU Y， LIOU J Y. Efficacy of Ethanol Ablation for Benign Thyroid Cysts and Predominantly Cystic Nodules： A Systematic Review and Meta-Analysis［J］. Endocrinol Metab （Seoul）， 2021， 36（1）：81-95. doi： 10.3803/EnM.2020.833 .
[7] LIN Y， LI P， SHI Y P， et al. Sequential treatment by polidocanol and radiofrequency ablation of large benign partially cystic thyroid nodules with solid components： Efficacy and safety［J］. Diagn Interv Imaging， 2020， 101（6）：365-372. doi： 10.1016/j.diii.2019.11.005 .
[8] 徐萍， 徐岷， 葛璐， 等. 超声引导下微波消融单次治疗多发甲状腺结节的疗效和安全性评估［J］. 实用医学杂志， 2018， 34（1）： 96-99. doi：10.3969/j.issn.1006-5725.2018.01.024 .
[9] CRESPO VALLEJO E， HERMOSIN A， GARGALLO M， et al. Multiple overlapping microwave ablation in benign thyroid nodule： A single-center 24-month study［J］. Eur Thyroid J， 2023， 12（1）：e220175. doi： 10.1530/ETJ-22-0175 .
[10] 黄玉慧， 宋宇， 付尧， 等. 甲状腺囊实性结节微波消融方案及术中囊内出血的影响因素［J］. 中国医学影像学杂志， 2022， 30（9）： 927-932， 940.doi： 10.3969/j.issn.1005-5185. 2022. 09.010 .
[11] ZHANG Y， CHU X， LIU Y， et al. The influence of nodule size on clinical efficacy of ethanol ablation and microwave ablation on cystic or predominantly cystic thyroid nodules［J］. Endocr Connect， 2022， 11（11）： e220248. doi： 10.1530/EC-22-0248 .
[12] MIN X， ZHANG Z， CHEN Y， et al. Comparison of the effectiveness of lauromacrogol injection for ablation and microwave ablation in the treatment of predominantly cystic thyroid nodules： A multicentre study［J］. BMC Cancer， 2023， 23（1）： 785. doi： 10.1186/s12885-023-11301-7 .
[13] 黎秀娜， 刘美婷， 罗运红， 等. 超声引导下微波消融联合聚桂醇硬化治疗囊性为主甲状腺结节的疗效评价［J］.现代医用影像学， 2022， 31（7）： 1356-1360， 1364.doi： 10.3969/j.issn. 1006- 7035.2022.07.048 .
[14] DONG Y J， LIU Z H， ZHOU J Q， et al. Efficacy of Lauromacrogol Injection for Ablation of Benign Predominantly Cystic Thyroid Nodules and Related Factors： A Prospective Study［J］. Korean J Radiol， 2022， 23（4）： 479-487. doi： 10.3348/kjr.2020.1205 .
[15] SINCLAIR C F， BAEK J H， HANDS K E， et al. General Principles for the Safe Performance， Training， and Adoption of Ablation Techniques for Benign Thyroid Nodules： An American Thyroid Association Statement［J］. Thyroid，2023，33（10）：1150-1170. doi： 10.1089/thy.2023.0281 .
[16] YANG S， HUANG D. Application of ultrasound-guided microwave ablation combined with polidocanol injection in benign cystic-solid thyroid nodules and recurrence analysis［J］. Discov Oncol， 2025， 16（1）：736. doi： 10.1007/s12672-025-02533-z .
[17] 付倩倩， 吴翠萍， 王诗雨， 等. 超声引导下微波消融治疗甲状腺良性结节效果及其影响因素［J］. 中国介入影像与治疗学， 2021， 18（7）： 393-397. doi：10.13929/j.issn.1672-8475. 2021. 07.003 .
[18] LUO F， HUANG L， GONG X， et al. Microwave ablation of benign thyroid nodules： 3-year follow-up outcomes［J］. Head Neck， 2021， 43（11）： 3437-3447. doi： 10.1002/hed.26842 .
[19] 夏林玉， 胡清林. 微波消融术治疗甲状腺良性结节的疗效及影响因素分析［J］. 中国现代医学杂志，2022， 32（9）： 73-77. doi：10.3969/j.issn.1005-8982.2022.09.012 .
[20] 郭卫红， 黄晓云， 刘曙艳， 等. 超声引导下微波消融对甲状腺良性结节的疗效及其预后影响因素分析［J］. 实用临床医药杂志， 2024， 28（16）： 5-9. doi： 10.7619/jcmp.20233139 .
Options
Outlines

/

〈 〉